The suppressive efficacy of THZ1 depends on <i>KRAS</i> mutation subtype and is associated with super‐enhancer activity and the PI3K/AKT/mTOR signalling in pancreatic ductal adenocarcinoma: A hypothesis‐generating study
Clinical and translational medicine